References
- Humbert M, Morrell N W, Archer S L, Stenmark K R, MacLean M R, Lang I M, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(Suppl)13S–24S
- Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425–1436
- Cool C D, Rai P R, Yeager M E, Hernandez-Saavedra D, Serls A E, Bull T M, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349: 1113–1112
- Gupta R, Perumandla S, Patsiornik Y, Niranjan S, Ohri A. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. J Natl Med Assoc 2006; 98: 1779–1782
- Dingli D, Utz P J, Gertz M. Pulmonary hypertension in patients with amyloidosis. Chest 2001; 120: 1735–1739
- Shiue S T, McNally D P. Pulmonary hypertension from prominent vascular involvement in diffuse amyloidosis. Arch Int Med 1998; 148: 687–689
- Korecki J, Kaminski K A, Lisowska A, Musial W J. Supraventricular tachycardia and pulmonary hypertension at the presentation of Hodgkin's disease. Acta Cardiol 2005; 60: 655–657
- Aouba A, Diop S, Saadoun D, Trebbia G, Vilde F, Patri B, et al. Severe pulmonary arterial hypertension as initial manifestation of intravascular lymphoma: case report. Am J Hematol 2005; 79: 46–49
- Younis T H. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Br J Haematol 2003; 121: 191–192
- Albertson T E, Walby W F, Derlet R W. Stimulant-induced pulmonary toxicity. Chest 1995; 108: 1140–1149
- http://sweweb.mpa.se/swedisii/; Accessed on 20 August, 2007.
- http://www.who-umc.org/; Accessed on 20 August, 2007.
- Gonzalez-Lopez L, Cardona-Munoz E G, Celis A, Garcia-de la Torre I, Orozco-Barocio G, Salazar-Paramo M, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 2004; 13: 105–112